Gallant J E, Moore R D, Keruly J, Richman D D, Chaisson R E
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287-6220, USA.
J Infect Dis. 1995 Aug;172(2):346-52. doi: 10.1093/infdis/172.2.346.
To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and < or = 250 CD4 cells/mm3 following initiation of zidovudine were analyzed. Of these patients, 336 (32%) received regular acyclovir (> or = 6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or < 100 CD4 cells/mm3 at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P = .057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.
为评估阿昔洛韦使用与晚期人类免疫缺陷病毒感染患者生存率之间的关联，我们分析了1044例艾滋病或艾滋病相关综合征（ARC）患者在开始使用齐多夫定后CD4细胞计数≤250个/mm³的观察数据。在这些患者中，336例（32%）接受了常规阿昔洛韦治疗（2个月内≥6周）。总体而言，阿昔洛韦使用者和非使用者的死亡率数据没有差异，在首次使用齐多夫定1年后分析、从入组时患有ARC的患者的艾滋病发病时间分析、从入组时患有艾滋病或CD4细胞计数<100个/mm³的患者分析，或从服用阿昔洛韦长达10个月的患者分析时，均无差异。阿昔洛韦的使用与死亡率增加相关（相对风险，1.28；P = 0.057），与疱疹病毒感染以及其他与死亡率相关的特征无关。在本研究中，将用于治疗单纯疱疹病毒感染剂量的阿昔洛韦与齐多夫定联合使用与延长生存期无关。
